date:Feb 21, 2013
Royal DSM has reported a broadly flat sales performance for 4Q12 and for the full year. Operating profit, however, fell by 28% in the quarter and 27% for the year, with gains in nutrition more than offset by reductions in the companys polymer intermediates business. Net profit was down 75% for the quarter, and 65% for the year.
The company described its performance as solid, and said that it was positioned for stromg EBITDA growth.
In the context of challenging macro-economic conditions, DSM d